The Dutch healthcare institute (ZIN), which conducts health technology appraisals in the Netherlands, has advised the ministry of health to join forces with Ireland and Belgium when it negotiates pricing and reimbursement conditions for Novartis’s gene therapy Zolgensma (onasemnogene abeparvovec). Novartis says talks on the matter with the three countries are underway.
ZIN has also slammed Vertex for requesting a high price for its cystic fibrosis combination treatment Kaftrio and has advised...








